Shanghai Kaibao Pharmaceutical Co., Ltd.

  • Market Cap: Small Cap
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: CNE100000JZ3
CNY
4.39
0.15 (3.54%)
  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-recommendationScore
Click here to find our call on this stock
Strong Sell
Sell
Hold
Buy
Strong Buy

Comparison

Company
Score
Quality
Valuation
Financial
Technical
Shanghai Kaibao Pharmaceutical Co., Ltd.

Why is Shanghai Kaibao Pharmaceutical Co., Ltd. ?

1
Poor long term growth as Net Sales has grown by an annual rate of 1.64% and Operating profit at 23.85% over the last 5 years
2
With a fall in Net Profit of -23.05%, the company declared Very Negative results in Mar 26
  • The company has declared negative results for the last 6 consecutive quarters
  • INTEREST(HY) At CNY 0.06 MM has Grown at 37.35%
  • OPERATING CASH FLOW(Y) Lowest at CNY 291.47 MM
  • NET SALES(Q) At CNY 283.25 MM has Fallen at -29.3%
3
Consistent Underperformance against the benchmark over the last 3 years
  • Along with generating -28.38% returns in the last 1 year, the stock has also underperformed China Shanghai Composite in each of the last 3 annual periods
stock-recommendationReal-Time Research Report

Verdict Report

How much should you sell?

  1. All quantity irrespective of whether you are making profits or losses

(If sector exposure > 30%, please use optimiser tool to see which are the best stocks to hold in Pharmaceuticals & Biotechnology)

When to re-enter? - We will constantly monitor the company and review our call based on new data

Is Shanghai Kaibao Pharmaceutical Co., Ltd. for you?

Medium Risk, Low Return

Absolute
Risk Adjusted
Volatility
Shanghai Kaibao Pharmaceutical Co., Ltd.
-26.34%
-0.99
25.19%
China Shanghai Composite
23.91%
1.73
13.79%
stock-recommendationQuality
stock-summaryManagement Risk
stock-summaryGrowth
stock-summaryCapital Structure
stock-recommendation
Quality grade scale :

Below Average, Average, Good, Excellent

Quality key factors

Factor
Value
Sales Growth (5y)
1.64%
EBIT Growth (5y)
23.85%
EBIT to Interest (avg)
100.00
Debt to EBITDA (avg)
0
Net Debt to Equity (avg)
-0.21
Sales to Capital Employed (avg)
0.34
Tax Ratio
15.03%
Dividend Payout Ratio
48.82%
Pledged Shares
0
Institutional Holding
0
ROCE (avg)
8.20%
ROE (avg)
6.40%
stock-recommendationValuation

Valuation Scorecard stock-summary

stock-recommendation
Valuation grade scale :

Very Risky, Risky, Very Expensive, Expensive, Fair, Attractive, Very Attractive

Valuation Key Factors stock-summary

Factor
Value
P/E Ratio
20
Industry P/E
Price to Book Value
1.14
EV to EBIT
17.62
EV to EBITDA
15.85
EV to Capital Employed
1.18
EV to Sales
4.08
PEG Ratio
NA
Dividend Yield
2.56%
ROCE (Latest)
6.68%
ROE (Latest)
5.70%
stock-recommendationTechnicals

Technical key factors

Indicator
Weekly
Monthly
MACD
Bearish
Bearish
RSI
Bullish
No Signal
Bollinger Bands
Mildly Bearish
Bearish
Moving Averages
Bearish (Daily)
KST
Bearish
Bearish
Dow Theory
Mildly Bearish
Mildly Bearish
OBV
Mildly Bearish
Mildly Bearish
stock-recommendation Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish  Turned 
Technical Movement
stock-recommendationFinancial Trend

Financial Trend Scorecard stock-summary

stock-recommendation
Financial Trend scale:

Very Negative, Negative, Flat, Positive, Very Positive, Outstanding

1What is working for the Company
RAW MATERIAL COST(Y)

Fallen by -0.35% (YoY

-35What is not working for the Company
INTEREST(HY)

At CNY 0.06 MM has Grown at 37.35%

OPERATING CASH FLOW(Y)

Lowest at CNY 291.47 MM

NET SALES(Q)

At CNY 283.25 MM has Fallen at -29.3%

NET PROFIT(HY)

At CNY 166.47 MM has Grown at -30.91%

ROCE(HY)

Lowest at 5.83%

INVENTORY TURNOVER RATIO(HY)

Lowest at 1.18 times

INTEREST COVERAGE RATIO(Q)

Lowest at 173,993.2

DEBTORS TURNOVER RATIO(HY)

Lowest at 2.19 times

PRE-TAX PROFIT(Q)

Fallen at -26.35%

Here's what is working for Shanghai Kaibao Pharmaceutical Co., Ltd.

Raw Material Cost
Fallen by -0.35% (YoY)
MOJO Watch
The company's ability to pass on the cost of raw materials to customers has improved; this may lead to a rise in profit margin

Raw Material Cost as a percentage of Sales

Here's what is not working for Shanghai Kaibao Pharmaceutical Co., Ltd.

Interest
At CNY 0.06 MM has Grown at 37.35%
over previous Semi-Annual period
MOJO Watch
Rising interest cost signifies increased borrowings

Interest Paid (CNY MM)

Net Sales
At CNY 283.25 MM has Fallen at -29.3%
Year on Year (YoY)
MOJO Watch
Near term sales trend is extremely negative

Net Sales (CNY MM)

Operating Cash Flow
Lowest at CNY 291.47 MM and Fallen
In each year in the last three years
MOJO Watch
The company's cash revenues from business operations are falling

Operating Cash Flows (CNY MM)

Interest Coverage Ratio
Lowest at 173,993.2
in the last five periods
MOJO Watch
The company's ability to manage interest payments is deteriorating

Operating Profit to Interest

Net Profit
At CNY 166.47 MM has Grown at -30.91%
Year on Year (YoY)
MOJO Watch
Near term Net Profit trend is negative

Net Profit (CNY MM)

Inventory Turnover Ratio
Lowest at 1.18 times and Fallen
In each half year in the last five Semi-Annual periods
MOJO Watch
Company's pace of selling inventory has slowed

Inventory Turnover Ratio

Pre-Tax Profit
Fallen at -26.35%
Year on Year (YoY)
MOJO Watch
Near term Pre-Tax Profit trend is negative

Pre-Tax Profit (CNY MM)

Debtors Turnover Ratio
Lowest at 2.19 times
in the last five Semi-Annual periods
MOJO Watch
Company's pace of selling Debtors has slowed

Debtors Turnover Ratio